---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-103160"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2024-09-26T23:59:59+00:00"
generated_at: "2026-05-31T01:43:41.769013+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Armata VP Corporate Controller Richard Rychlik to depart on Sept 30, 2024

## Summary
- Richard Rychlik, VP and Corporate Controller, will leave Armata effective September 30, 2024.
- Separation agreement terms are still being negotiated between Rychlik and the company.
- No successor named; role of Corporate Controller is currently unstaffed.

## SEC filing metadata
- accession: 0001104659-24-103160
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2024-09-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465924103160/0001104659-24-103160-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465924103160/tm2425034d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-103160
- JSON: https://secwatch.observer/filing/0001104659-24-103160.json
- Plain text: https://secwatch.observer/filing/0001104659-24-103160.txt

## Key facts
- Executive change
  Richard Rychlik departed as Vice President, Corporate Controller at Armata Pharmaceuticals, Inc..
  - Role: Vice President, Corporate Controller
  source text: reached an agreement with Richard Rychlik, the Company’s Vice President, Corporate Controller, pursuant to which Mr. Rychlik’s employment will conclude effective as of September 30, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921114/000110465924103160/0001104659-24-103160-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.